189 related articles for article (PubMed ID: 18609705)
21. The potential role of hypoxia inducible factor 1alpha in tumor progression after hypoxia and chemotherapy in hepatocellular carcinoma.
Yang ZF; Poon RT; To J; Ho DW; Fan ST
Cancer Res; 2004 Aug; 64(15):5496-503. PubMed ID: 15289360
[TBL] [Abstract][Full Text] [Related]
22. HBV transcription repression in response to genotoxic stress is p53-dependent and abrogated by pX.
Doitsh G; Shaul Y
Oncogene; 1999 Dec; 18(52):7506-13. PubMed ID: 10602509
[TBL] [Abstract][Full Text] [Related]
23. Defective DNA damage response and repair in liver cells expressing hepatitis B virus surface antigen.
Chung YL
FASEB J; 2013 Jun; 27(6):2316-27. PubMed ID: 23444429
[TBL] [Abstract][Full Text] [Related]
24. Cross talk between PML and p53 during poliovirus infection: implications for antiviral defense.
Pampin M; Simonin Y; Blondel B; Percherancier Y; Chelbi-Alix MK
J Virol; 2006 Sep; 80(17):8582-92. PubMed ID: 16912307
[TBL] [Abstract][Full Text] [Related]
25. Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner.
Haupt S; Mitchell C; Corneille V; Shortt J; Fox S; Pandolfi PP; Castillo-Martin M; Bonal DM; Cordon-Cardo C; Lozano G; Haupt Y
Cell Cycle; 2013 Jun; 12(11):1722-31. PubMed ID: 23656786
[TBL] [Abstract][Full Text] [Related]
26. MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro.
Wang J; Zheng T; Chen X; Song X; Meng X; Bhatta N; Pan S; Jiang H; Liu L
J Gastroenterol Hepatol; 2011 Feb; 26(2):371-7. PubMed ID: 21261729
[TBL] [Abstract][Full Text] [Related]
27. BMK1 is involved in the regulation of p53 through disrupting the PML-MDM2 interaction.
Yang Q; Liao L; Deng X; Chen R; Gray NS; Yates JR; Lee JD
Oncogene; 2013 Jun; 32(26):3156-64. PubMed ID: 22869143
[TBL] [Abstract][Full Text] [Related]
28. Enhancement of carboplatin- and quercetin-induced cell death by roscovitine is Akt dependent and p53 independent in hepatoma cells.
Sharma A; Bhat MK
Integr Cancer Ther; 2011 Dec; 10(4):NP4-14. PubMed ID: 21994207
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic targeting of nuclear receptor corepressor misfolding in acute promyelocytic leukemia cells with genistein.
Ng AP; Nin DS; Fong JH; Venkataraman D; Chen CS; Khan M
Mol Cancer Ther; 2007 Aug; 6(8):2240-8. PubMed ID: 17699721
[TBL] [Abstract][Full Text] [Related]
30. [Study on synergistic effect of sodium cantharidinate combined with chemotherapeutic drugs on hepatic carcinoma and its effective mechanism].
Zhao RL; Chen MJ; Zhao FM; Xu DQ; Zhang X; Zhou KF
Zhong Yao Cai; 2014 Nov; 37(11):1938-46. PubMed ID: 26027111
[TBL] [Abstract][Full Text] [Related]
31. The apoptotic effect and associated signalling of HSP90 inhibitor 17-DMAG in hepatocellular carcinoma cells.
Leng AM; Liu T; Yang J; Cui JF; Li XH; Zhu YN; Xiong T; Zhang G; Chen Y
Cell Biol Int; 2012 Oct; 36(10):893-9. PubMed ID: 22694478
[TBL] [Abstract][Full Text] [Related]
32. A novel resveratrol analogue HS-1793 treatment overcomes the resistance conferred by Bcl-2 and is associated with the formation of mature PML nuclear bodies in renal clear cell carcinoma Caki-1 cells.
Jeong SH; Lee JS; Jeong NY; Kim TH; Yoo KS; Song S; Suh H; Kwon TK; Park BS; Yoo YH
Int J Oncol; 2009 Dec; 35(6):1353-60. PubMed ID: 19885558
[TBL] [Abstract][Full Text] [Related]
33. Promyelocytic leukemia protein is required for gain of function by mutant p53.
Haupt S; di Agostino S; Mizrahi I; Alsheich-Bartok O; Voorhoeve M; Damalas A; Blandino G; Haupt Y
Cancer Res; 2009 Jun; 69(11):4818-26. PubMed ID: 19487292
[TBL] [Abstract][Full Text] [Related]
34. Induction of apoptosis by pectenotoxin-2 is mediated with the induction of DR4/DR5, Egr-1 and NAG-1, activation of caspases and modulation of the Bcl-2 family in p53-deficient Hep3B hepatocellular carcinoma cells.
Shin DY; Kim GY; Kim ND; Jung JH; Kim SK; Kang HS; Choi YH
Oncol Rep; 2008 Feb; 19(2):517-26. PubMed ID: 18202802
[TBL] [Abstract][Full Text] [Related]
35. Telomerase suppression initiates PML-dependent p53 activation to inhibit bladder cancer cell growth.
Xue Y; Li L; Zhang D; Wu K; Guo P; Zeng J; Wang X; He D
Oncol Rep; 2010 Dec; 24(6):1551-9. PubMed ID: 21042751
[TBL] [Abstract][Full Text] [Related]
36. Novel combinational treatment of cisplatin with cyclophilin A inhibitors in human heptocellular carcinomas.
Lee J
Arch Pharm Res; 2010 Sep; 33(9):1401-9. PubMed ID: 20945139
[TBL] [Abstract][Full Text] [Related]
37. Epigenetic silencing of BCL6B inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-FU.
Li X; Yu J; Brock MV; Tao Q; Herman JG; Liang P; Guo M
Oncotarget; 2015 May; 6(13):11547-60. PubMed ID: 25909168
[TBL] [Abstract][Full Text] [Related]
38. 3,5-Dimethyl-H-furo[3,2-g]chromen-7-one as a potential anticancer drug by inducing p53-dependent apoptosis in human hepatoma HepG2 cells.
Sun JG; Chen CY; Luo KW; Yeung CL; Tsang TY; Huang ZZ; Wu P; Fung KP; Kwok TT; Liu FY
Chemotherapy; 2011; 57(2):162-72. PubMed ID: 21454974
[TBL] [Abstract][Full Text] [Related]
39. 5-Fluorouracil combined with apigenin enhances anticancer activity through mitochondrial membrane potential (ΔΨm)-mediated apoptosis in hepatocellular carcinoma.
Hu XY; Liang JY; Guo XJ; Liu L; Guo YB
Clin Exp Pharmacol Physiol; 2015 Feb; 42(2):146-53. PubMed ID: 25363523
[TBL] [Abstract][Full Text] [Related]
40. Identification of Daxx interacting with p73, one of the p53 family, and its regulation of p53 activity by competitive interaction with PML.
Kim EJ; Park JS; Um SJ
Nucleic Acids Res; 2003 Sep; 31(18):5356-67. PubMed ID: 12954772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
